Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AMOTL2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AMOTL2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AMOTL2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
GO:003001018 | Esophagus | ESCC | establishment of cell polarity | 96/8552 | 143/18723 | 1.69e-07 | 2.67e-06 | 96 |
GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
GO:00353297 | Esophagus | ESCC | hippo signaling | 26/8552 | 40/18723 | 1.08e-02 | 3.66e-02 | 26 |
GO:000716318 | Oral cavity | OSCC | establishment or maintenance of cell polarity | 129/7305 | 218/18723 | 1.16e-09 | 2.86e-08 | 129 |
GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
GO:003001016 | Oral cavity | OSCC | establishment of cell polarity | 82/7305 | 143/18723 | 6.56e-06 | 7.24e-05 | 82 |
GO:000166719 | Oral cavity | OSCC | ameboidal-type cell migration | 228/7305 | 475/18723 | 3.46e-05 | 3.10e-04 | 228 |
GO:000716319 | Oral cavity | LP | establishment or maintenance of cell polarity | 79/4623 | 218/18723 | 8.84e-05 | 1.11e-03 | 79 |
GO:001605515 | Oral cavity | LP | Wnt signaling pathway | 140/4623 | 444/18723 | 5.80e-04 | 5.35e-03 | 140 |
GO:019873815 | Oral cavity | LP | cell-cell signaling by wnt | 140/4623 | 446/18723 | 7.12e-04 | 6.38e-03 | 140 |
GO:003001017 | Oral cavity | LP | establishment of cell polarity | 49/4623 | 143/18723 | 6.33e-03 | 3.73e-02 | 49 |
GO:000166728 | Thyroid | HT | ameboidal-type cell migration | 52/1272 | 475/18723 | 4.54e-04 | 5.53e-03 | 52 |
GO:000716328 | Thyroid | HT | establishment or maintenance of cell polarity | 28/1272 | 218/18723 | 8.66e-04 | 9.20e-03 | 28 |
GO:001605520 | Thyroid | HT | Wnt signaling pathway | 48/1272 | 444/18723 | 9.68e-04 | 9.93e-03 | 48 |
GO:019873820 | Thyroid | HT | cell-cell signaling by wnt | 48/1272 | 446/18723 | 1.07e-03 | 1.07e-02 | 48 |
GO:00353298 | Thyroid | HT | hippo signaling | 8/1272 | 40/18723 | 4.84e-03 | 3.32e-02 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AMOTL2 | SNV | Missense_Mutation | novel | c.1282N>A | p.Glu428Lys | p.E428K | Q9Y2J4 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AMOTL2 | SNV | Missense_Mutation | | c.355G>A | p.Glu119Lys | p.E119K | Q9Y2J4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
AMOTL2 | insertion | Nonsense_Mutation | novel | c.1562_1563insATTACAGGCATGAGC | p.Gly521_Asn522insLeuGlnAlaTerAla | p.G521_N522insLQA*A | Q9Y2J4 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AMOTL2 | SNV | Missense_Mutation | novel | c.803N>A | p.Pro268Gln | p.P268Q | Q9Y2J4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AMOTL2 | SNV | Missense_Mutation | | c.2410G>C | p.Asp804His | p.D804H | Q9Y2J4 | protein_coding | deleterious(0.03) | possibly_damaging(0.501) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
AMOTL2 | SNV | Missense_Mutation | novel | c.551N>A | p.Pro184Gln | p.P184Q | Q9Y2J4 | protein_coding | tolerated(0.23) | benign(0.282) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
AMOTL2 | SNV | Missense_Mutation | novel | c.1940C>T | p.Thr647Met | p.T647M | Q9Y2J4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AMOTL2 | SNV | Missense_Mutation | novel | c.1132N>C | p.Glu378Gln | p.E378Q | Q9Y2J4 | protein_coding | tolerated(0.12) | possibly_damaging(0.477) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
AMOTL2 | SNV | Missense_Mutation | novel | c.1159N>A | p.Glu387Lys | p.E387K | Q9Y2J4 | protein_coding | deleterious(0.02) | possibly_damaging(0.541) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AMOTL2 | SNV | Missense_Mutation | novel | c.1243N>A | p.Glu415Lys | p.E415K | Q9Y2J4 | protein_coding | deleterious(0.02) | probably_damaging(0.913) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |